A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 18 Dec 2008
At a glance
- Drugs Imiglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 10 Jun 2017 Biomarkers information updated
- 18 Dec 2008 Planned number of patients (302) added as reported by ClinicalTrials.gov.
- 18 Oct 2008 New trial record.